WO2004073724A1 - Composition pharmaceutique endogene, obtenue par une activation dirigee des mediateurs humoraux de terminaisons nerveuses du cortex - Google Patents

Composition pharmaceutique endogene, obtenue par une activation dirigee des mediateurs humoraux de terminaisons nerveuses du cortex Download PDF

Info

Publication number
WO2004073724A1
WO2004073724A1 PCT/RU2004/000051 RU2004000051W WO2004073724A1 WO 2004073724 A1 WO2004073724 A1 WO 2004073724A1 RU 2004000051 W RU2004000051 W RU 2004000051W WO 2004073724 A1 WO2004073724 A1 WO 2004073724A1
Authority
WO
WIPO (PCT)
Prior art keywords
sinaπτοsοmy
neρvnyχ
zhivοτnyχ
gumορalnyχ
endogenous
Prior art date
Application number
PCT/RU2004/000051
Other languages
English (en)
Russian (ru)
Inventor
Nina Maksimovna Pinigina
Ludmila Anatolievna Latserus
Feliks Edmundovich Latserus
Original Assignee
Nina Maksimovna Pinigina
Ludmila Anatolievna Latserus
Feliks Edmundovich Latserus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nina Maksimovna Pinigina, Ludmila Anatolievna Latserus, Feliks Edmundovich Latserus filed Critical Nina Maksimovna Pinigina
Publication of WO2004073724A1 publication Critical patent/WO2004073724A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention is subject to the field of medicine and biotechnology and is related to pharmaceuticals based on the use of mediation and the use of it.
  • SIGNIFICANT FOX P ⁇ IL 26 Pa ⁇ alleln ⁇ e ⁇ azvi ⁇ ie ⁇ ev ⁇ lyutsi ⁇ nny ⁇ v ⁇ zz ⁇ eny on v ⁇ zm ⁇ zhn ⁇ s ⁇ ⁇ lucheniya n ⁇ vy ⁇ le ⁇ a ⁇ s ⁇ v ⁇ u ⁇ em v ⁇ s ⁇ izvedeniya and vid ⁇ izmeneniya es ⁇ es ⁇ venny ⁇ end ⁇ genny ⁇ s ⁇ edineny ⁇ as ⁇ eny, and zhiv ⁇ ny ⁇ chel ⁇ ve ⁇ a and ⁇ a ⁇ same ⁇ az ⁇ ab ⁇ a n ⁇ vy ⁇ me ⁇ d ⁇ v ( ⁇ a ⁇ i ⁇ , na ⁇ ime ⁇ , ⁇ a ⁇ s ⁇ laysing - or ⁇ e ⁇ mbinan ⁇ naya D ⁇ ⁇ e ⁇ n ⁇ l ⁇ giya, gene inzhene ⁇ iya and ⁇ .d.)
  • Endogenous compounds are detected in the process of the destruction of the mechanisms of the pathogenesis of various diseases.
  • the “start-up” path results from the immediate endogenous disasters that are likely to block the occurrence of disturbances in the regulation of normal physical processes.
  • E ⁇ mu s ⁇ s ⁇ bs ⁇ vue ⁇ s ⁇ emi ⁇ eln ⁇ e ⁇ azvi ⁇ ie s ⁇ v ⁇ emenn ⁇ y issled ⁇ va ⁇ els ⁇ y ⁇ e ⁇ ni ⁇ i and is ⁇ lz ⁇ vanie v ⁇ z- ni ⁇ shi ⁇ v ⁇ zm ⁇ zhn ⁇ s ⁇ ey ⁇ vedeniya e ⁇ s ⁇ e ⁇ imen ⁇ alny ⁇ ⁇ ab ⁇ on ⁇ ul ⁇ u ⁇ e ⁇ le ⁇ " ⁇ chech- n ⁇ y" immun ⁇ gis ⁇ imii, ⁇ e ⁇ n ⁇ l ⁇ gii m ⁇ le ⁇ ulya ⁇ n ⁇ g ⁇ ⁇ l ⁇ ni ⁇ vaniya and ⁇ a ⁇ same ⁇ ivlechenie ⁇ m ⁇ y ⁇ e ⁇ n ⁇ y ⁇ e ⁇ n ⁇ l ⁇ gii.
  • SIGNIFICANT FOX (DR. 26) management, treatment of addiction, storage and treatment of information by neurons of the main brain, the development and development of diseases, etc.
  • SIGNIFICANT FOX Particulars, cities, limfokins (interleukins, interfeys, ⁇ and t.d.), factors of a growth, neurotransmitters or their occurrences, is t.d.), methods ( ⁇ , ⁇ , ⁇ , and t.d.), disstructin, minidistruffin, gene-critical events, or genes that are involved in the outcomes of the process .
  • ne ⁇ s ⁇ i maya bi ⁇ l ⁇ giches ⁇ aya a ⁇ iv- n ⁇ s ⁇ e ⁇ i ⁇ s ⁇ eds ⁇ v not ⁇ zv ⁇ lyae ⁇ ⁇ intsi ⁇ ialn ⁇ ⁇ eshi ⁇ ⁇ blemu e ⁇ e ⁇ ivn ⁇ g ⁇ ⁇ u ⁇ i ⁇ - Bani ⁇ znachenny ⁇ ⁇ a ⁇ l ⁇ giches ⁇ i ⁇ s ⁇ s ⁇ yany, ⁇ em b ⁇ lee ⁇ a ⁇ i ⁇ ⁇ a ⁇ u ⁇ levye ⁇ tsessy, ⁇ a ⁇ ⁇ a ⁇ in ⁇ sn ⁇ ve e ⁇ i ⁇ ⁇ ab ⁇ were is ⁇ lz ⁇ vany knowledge ⁇ delny ⁇ units ⁇ un ⁇ tsi ⁇ ni ⁇ - Bani tsen ⁇ aln ⁇ y n
  • SIGNIFICANT FOX (DR. 26) Combining with receptors, prevent the action of endogenous ligands, i.e. are their antagonisms.
  • the effect of synthetic neuropathic drugs may also be related to the impact on the biosynthesis and metabolism of a non-mediated business.
  • a pharmaceutical combination of muscle cells or leukocytes (I8, P_, holderp. ⁇ 61 ⁇ 35/34; 35/16, ⁇ 12 ⁇ 1 / 00, ⁇ 01 ⁇ 233 / 50 // ( ⁇ 12 ⁇ 1 1:91) is also proposed.
  • South Africa is also a pool of proteins isolated from the tsuni of the recent occupation of the people ( ⁇ ⁇ ° 2055589, class ⁇ 61 ⁇ 35/44; 1996), which is free of charge for the human being.
  • P ⁇ ed ⁇ ini mayu ⁇ sya ⁇ y ⁇ i treatment with zl ⁇ aches ⁇ venny ⁇ ⁇ b ⁇ az ⁇ vany ⁇ m ⁇ schyu v ⁇ lyucheniya vnu ⁇ enni ⁇ ⁇ esu ⁇ s ⁇ v ⁇ ganizma, is ⁇ lzuya for e ⁇ g ⁇ subs ⁇ a ⁇ , ⁇ luchenny ⁇ u- ⁇ em ⁇ az ⁇ usheniya na ⁇ ivny ⁇ zl ⁇ aches ⁇ venny ⁇ ⁇ le ⁇ , ⁇ y hereinafter vys ⁇ u ⁇ ae ⁇ in ⁇ li su ⁇ ess ⁇ n ⁇ - ⁇ ille ⁇ ny ⁇ ⁇ - ⁇ le ⁇ .
  • angiogenesis inhibitors can increase the development of the disease by not neglecting the benefits of the disease.
  • the reversible character is due to a significant violation of the integrity of the structure or non-collapsing negative impact. Even plants are capable of following this growth. ⁇ réelle ⁇ ⁇ ⁇ Giveaway ⁇ réelle ⁇ ⁇ . in response to the impact of stress, cost-effective, low temperatures or dysfunctional diseases, there is a loss of consciousness. It has been established that the degree of non-saturation of fatty acids of lipids is increased, the synthesis of low-fatty acids and the most volatile fatty acids are enhanced. By the way, in the case of cold, to prevent the formation of live ice cages, lipids are synthesized by a liquid supply, and in the case of a short circuit, the supply of food is increased.
  • the purpose of the invention is the creation of an effective com- petition for the purchase of medical devices with the impairment of the synthesis of non-mediocre substances.
  • the task was solved by a new endogenous company, based on a complex of neuro-mediators from the main brain of the experimental main brain.
  • the indicated fraction preferably includes the synaptic system and the following protein content in mg / g of tissue: ⁇ -1.4-2.4; LS- 1.81- 2.41; ⁇ - 1.61-1.83.
  • Man, or -Papillomavirus of the person (U) can cause the attack of the neck of the mataka. .... ⁇ .... ⁇ .Ru ⁇ gu and ⁇ infect millions of people, but only some of them develop the disease.
  • ⁇ ⁇ tsesse ⁇ ab ⁇ y us was s ⁇ mi ⁇ vana " ⁇ ab ⁇ chaya gi ⁇ eza" ⁇ azvi ⁇ iya ⁇ u ⁇ le- vy ⁇ ⁇ tsess ⁇ v and imenn ⁇ - e ⁇ i ⁇ tsessy yavlyayu ⁇ sya sleds ⁇ viem na ⁇ usheniya ⁇ un ⁇ tsi ⁇ ni ⁇ va- Nia ⁇ si ⁇ s ⁇ ma ⁇ iches ⁇ y s ⁇ e ⁇ y tsen ⁇ aln ⁇ y ne ⁇ vn ⁇ y sis ⁇ emy zhivy ⁇ ⁇ ganizm ⁇ v and m ⁇ zga in chas ⁇ n ⁇ s ⁇ i.
  • ⁇ e is ⁇ lyuchal ⁇ s, ch ⁇ media ⁇ y, vy ⁇ aba ⁇ yvayuschiesya in sina ⁇ s ⁇ ma ⁇ in ⁇ e ⁇ i ⁇ d elimination ⁇ u ⁇ ley, m ⁇ gu ⁇ yavi ⁇ sya imenn ⁇ ⁇ a ⁇ imi nab ⁇ ami ⁇ egulya ⁇ ny ⁇ vesches ⁇ v, ⁇ ye budu ⁇ yavlya ⁇ sya ⁇ a ⁇ matsev ⁇ iches ⁇ imi ⁇ m ⁇ zitsiyami v ⁇ g ⁇ ⁇ yad ⁇ a, ⁇ ye hereinafter m ⁇ gu ⁇ is ⁇ lz ⁇ va ⁇ sya, ⁇ a ⁇ sam ⁇ s ⁇ ya ⁇ elnye le ⁇ a ⁇ s ⁇ vennye s ⁇ eds ⁇ va.
  • the substance Bisil was received by a known method ( ⁇ , ⁇ ° 2054945, cl. ⁇ 61 ⁇ 35/78, 02.27.96). On the part of the distributor, olive oil was used in combination with the substance Bisil and the distributor, and the registered one was 0.1: 10, respectively.
  • mice Males and females
  • the tumor the ascitic carcinoma of Erlich, was internally pleural.
  • Treatment was started after 48 hours, after being relieved.
  • they served as a live group, injected a quick release agent (olive oil), but did not indicate treatment.
  • mice For a group of mice that received treatment with an injection of a substance in the area, they received a dose of 100 mg / kg of body weight at the end of the course of 9 days, after that, it took about 9 days. The remaining mice survived for 60 days, without any signs of loss of life or any signs of physical harm.
  • a method for isolating a synapse function isolating a synapse function.
  • the loaf was homogenized in a glass homogenized with a standard paste in the medium of separation from the calculation: for 1 g of tissue 9 ml of medium, 2 g of 18 ml of medium of separation (8 - 10 ml)
  • the obtained homogenate of the centers was 10 minutes at 1500 ⁇ ( ⁇ -24, DG: 4000 rpm).
  • the garden provided a fraction of uncleaned nuclei (nucleus, unexploded cells, and large vessels). Harsh liquid is available and decanted and delivered.
  • the extract is dispersed in the original (18 ml) medium and is centrifuged for 10 minutes at 1,500. After this planting wastewater is absorbed, and the supernatant liquids I and II are used to unite the centrifugal liquids.
  • Combined supernatant liquids are centered on a separate ultra-centrifugal filter ( ⁇ -60 with an angular rotational speed of 8x50) at a rate of 20 min for separation.
  • the “uncleaned myocardial fraction” plant is suspended in b ml of a fine 0.32 ⁇ of sugar and layered to a small temperature, which is cooled for a further 30 - 40 minutes; 1.0; 1.1; 1,2; ⁇ saharoozy. Separation of 130,000 ⁇ for 30 minutes at an ultracentric rate, using ⁇ ⁇ . 3x50 ( ⁇ - 60).
  • the outermost layer of 0.8 ⁇ sugar is myelin, between 0.8 ⁇ and 1.0 ⁇ sugar is “light”, or chronic synaptic (LS), between 1.1 and 1.2 ⁇ sugar is “heavy”, or amine , synaptic processes ( ⁇ ), garden plants - mitochondria ( ⁇ ).
  • Received fractions are removed with the aid of a spare part, diluted with 0.15 sugar and planted at 20,000 ⁇ for 40 minutes (ultracentrate 60 °, -).
  • mice in the quality of the medical device, they introduced EF, received from the group of untreated (untreated) groups of mice with well-developed ascites. With this, there was a slight increase in the longevity of living animals, but the process of regression was not revealed (see table 1.)
  • mice that received an EF ⁇ treatment isolated from the brain of a living animal with a complete regression of an obstructive strain is an acute carcinoma of the disease. (see table 1) At the end of experience, defeat 2
  • mice from 60 used in the experiment There was no mention of any - either toxic occurrences.
  • the Sa-755 mammary gland carcinoma was found to be useful in a quantity of 50 mg of tumor tissue per mouse.
  • Experiments were taken on a mouse of the C57 ⁇ C ⁇ line, males weighing at least 20 g.
  • Treatment in experienced and on-site groups began after 48 hours.
  • the mice were injected with a solvent (olive oil) to mice.
  • the treatment was carried out by gentle injections of the substance. I got into the area of an empty stomach in a single dose of 100 mg / kg of live weight.
  • the interval between injections was 24 hours.
  • the information was given for 9 days.
  • a specific set of regulating substances was also obtained in the same way as Example 1.
  • the price criterion was used for calculating the load transfer, calculated as follows:
  • mice treated with the use of test (Table 2), there was a significant decrease in the rate of growth of the test, but not a high percentage of the regression.
  • the U-256 burst was carried over to the clean lines of the Histara line weighing 200 - 250 g to males and females in the fresh air.
  • Treatment was carried out with the use of a substance Bisil in the dose of 100 mg / kg live weight after 48 hours after the inoculation. He imposed ⁇ / ⁇ into the area of the occupation zone with an interval of 24 hours for 9 days.
  • ⁇ a ⁇ im ⁇ b ⁇ az ⁇ m is ⁇ lz ⁇ vanny contact ( ⁇ ime ⁇ y 1, 2, 3) s ⁇ s ⁇ b tselena ⁇ avlenn ⁇ y a ⁇ ivatsii sin ⁇ eza gum ⁇ alny ⁇ media ⁇ v ne ⁇ vny ⁇ ⁇ nchany, ⁇ e ⁇ b ⁇ az ⁇ vanny ⁇ in na ⁇ s ⁇ my Cu, appeared to usl ⁇ viem ⁇ mi ⁇ vaniya ⁇ edelenn ⁇ g ⁇ nab ⁇ a ⁇ egulya ⁇ ny ⁇ of Great sches ⁇ v in m ⁇ zge e ⁇ s ⁇ e ⁇ imen ⁇ alny ⁇ zhiv ⁇ ny ⁇ ⁇ u ⁇ len ⁇ si ⁇ eley and ⁇ zv ⁇ lil ⁇ susches ⁇ vi ⁇ i ⁇ ⁇ luchenie and is ⁇ lz ⁇ vanie in the quality of the endogenous pharmaceuticals.
  • ⁇ a ⁇ im ⁇ b ⁇ az ⁇ m is ⁇ lzuya u ⁇ azanny s ⁇ s ⁇ b tselena ⁇ avlenn ⁇ y a ⁇ ivatsii gum ⁇ al- ny ⁇ media ⁇ v ne ⁇ vny ⁇ ⁇ nchany ⁇ y g ⁇ l ⁇ vn ⁇ g ⁇ m ⁇ zga ⁇ i ⁇ azvi ⁇ ii and ⁇ u ⁇ i ⁇ vanii ⁇ azlichny ⁇ ⁇ a ⁇ l ⁇ giches ⁇ i ⁇ ⁇ tsess ⁇ v, m ⁇ zhn ⁇ ⁇ lucha ⁇ end ⁇ gennye ⁇ a ⁇ matsev ⁇ iches ⁇ ie ⁇ m ⁇ zitsii ⁇ ⁇ azlichny ⁇ ⁇ l ⁇ neny n ⁇ maln ⁇ g ⁇ ⁇ echeniya ⁇ izi ⁇ l ⁇ giches ⁇ i ⁇ ⁇ tsess ⁇ v (astsi ⁇ ny ⁇ a ⁇ , s ⁇ lid
  • P ⁇ luchennye e ⁇ s ⁇ e ⁇ imen ⁇ alnye imeyu ⁇ data value is not to ⁇ l ⁇ ⁇ lucheniya ⁇ intsi ⁇ ialn ⁇ n ⁇ vy ⁇ e ⁇ e ⁇ ivny ⁇ le ⁇ a ⁇ s ⁇ venny ⁇ s ⁇ eds ⁇ v, n ⁇ and ⁇ nimaniya susches ⁇ - vuyuschi ⁇ ⁇ d ⁇ d ⁇ v ⁇ treatment ⁇ azlichny ⁇ zab ⁇ levany and ⁇ ayu ⁇ e for us ⁇ eshn ⁇ y ⁇ tsen ⁇ i ⁇ e ⁇ - s ⁇ e ⁇ ivny ⁇ le ⁇ a ⁇ s ⁇ venny ⁇ s ⁇ eds ⁇ v, s ⁇ edi mn ⁇ g ⁇ chislenny ⁇ ⁇ yavlyayuschi ⁇ sya n ⁇ vy ⁇ left- ⁇ a ⁇ s ⁇ v, ⁇ u ⁇ em study i ⁇ effects on the
  • the formulated endogenous pharmaceuticals may not be received, but are subject to physical disruption.
  • mice of the group ** - ⁇ () ⁇ ))))))))) - -) - received from mice of the group.
  • mice (cured) from a group with ⁇ ⁇
  • ⁇ ⁇
  • ⁇ ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention appartient au domaine de la médecine et de la biotechnologie et concerne des moyens pour traiter des états pathologiques liés à la perturbation de la synthèse de neuromédiateurs. On a fondé théoriquement et on a indiqué un procédé radicalement nouveau de fabrication de médicaments au cours d'une expérience, sur l'exemple de la fabrication d'une composition pharmaceutique endogène. La composition pharmaceutique se présente comme une fraction subcellulaire de synaptosomes: les membranes cellulaires, les synaptosomes 'légers' et les synaptosomes 'lourds' obtenus à partir de la matière grise des grands hémisphères du cerveau des animaux d'expérience sur la base d'une modification dirigée des médiateurs humoraux de terminaisons nerveuses, transformés en synaptosomes, lors de l'évolution et de la régression de processus tumoraux. L'invention permet d'inhiber la croissance de cellules tumorales, d'augmenter la durée de vie des malades souffrant du carcinome ascitique d'Ehrlich, de l'adénocarcinome de la glande mammaire Ca-755 et du carcinome / sarcome de Walker - 256.
PCT/RU2004/000051 2003-02-19 2004-02-17 Composition pharmaceutique endogene, obtenue par une activation dirigee des mediateurs humoraux de terminaisons nerveuses du cortex WO2004073724A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2003104869 2003-02-19
RU2003104869/15A RU2244928C2 (ru) 2003-02-19 2003-02-19 Эндогенная фармацевтическая композиция, полученная на основе целенаправленной активации гуморальных медиаторов нервных окончаний коры головного мозга

Publications (1)

Publication Number Publication Date
WO2004073724A1 true WO2004073724A1 (fr) 2004-09-02

Family

ID=32906775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2004/000051 WO2004073724A1 (fr) 2003-02-19 2004-02-17 Composition pharmaceutique endogene, obtenue par une activation dirigee des mediateurs humoraux de terminaisons nerveuses du cortex

Country Status (2)

Country Link
RU (1) RU2244928C2 (fr)
WO (1) WO2004073724A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2727792C (fr) 2008-03-14 2017-07-25 Obschestvo S Ogranichennoi Otvetstvennostyu "Initium-Pharm" Composition pharmacologique antitumorale a base de terpenoides 'abissiline' possedant une action inhibitrice d'angiogenese
WO2013176564A1 (fr) * 2012-05-25 2013-11-28 Общество С Ограниченной Ответственностью "Инитиум-Фарм" Produit à base de terpénoïdes pour la prophylaxie et le traitement de l'athérosclérose et l'atténuation du syndrome métabolique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1165402A1 (ru) * 1983-09-21 1985-07-07 Горьковский государственный медицинский институт им.С.М.Кирова Способ получени малатдегидрогеназы из митохондрий головного мозга
RU2155063C1 (ru) * 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
US20030096787A1 (en) * 1993-07-13 2003-05-22 Michel Perricaudet Defective adenovirus vectors and use thereof in gene therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1165402A1 (ru) * 1983-09-21 1985-07-07 Горьковский государственный медицинский институт им.С.М.Кирова Способ получени малатдегидрогеназы из митохондрий головного мозга
US20030096787A1 (en) * 1993-07-13 2003-05-22 Michel Perricaudet Defective adenovirus vectors and use thereof in gene therapy
RU2155063C1 (ru) * 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEREDENINA S.B.M.: "Kletochnye mekhanizmy realizatsii farmakologicheskogo effekta", 1990, pages: 43 - 53 *

Also Published As

Publication number Publication date
RU2244928C2 (ru) 2005-01-20

Similar Documents

Publication Publication Date Title
Shorvon Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909–1958
Cairney et al. The neurobehavioural effects of kava
DE60132444T2 (de) Behandlung von reizkolon-syndrom oder -krankheit
de Oliveira et al. Developments on drug discovery and on new therapeutics: highly diluted tinctures act as biological response modifiers
Gao et al. Wasp venom possesses potential therapeutic effect in experimental models of rheumatoid arthritis
EP0424534A4 (en) Pharmaceutical preparation for treatment of mastitis in animals and humans
WO1990012584A1 (fr) Preparation ayant un action anti-inflammatoire, lactogene et stimulante, et procede pour sa fabrication
Barker et al. Neural repair, transplantation, and rehabilitation
Ghorbanpour et al. Combined effects of royal jelly and environmental enrichment against stress-induced cognitive and behavioral alterations in male rats: behavioral and molecular studies
Green Aloe vera extracts in equine clinical practice
WO2004073724A1 (fr) Composition pharmaceutique endogene, obtenue par une activation dirigee des mediateurs humoraux de terminaisons nerveuses du cortex
Acero et al. Bedside to bench: the outlook for psychedelic research
TW202304490A (zh) 一種海木耳萃取物及其用途
WO2010017403A2 (fr) Compositions thérapeutiques, dispositifs et procédés pour l'observation de tissus traités
RU2739491C1 (ru) Средство для профилактики и лечения астенозооспермии и тератозооспермии
EP4181904A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
Chan The Dawn of New Medicine: Stem Cell Therapy: Old Dogma, New Hope
WO2022017959A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes d'épilepsies rares associés à des anomalies génétiques
RU2145216C1 (ru) Способ лечения хронического алкоголизма
RU2300376C2 (ru) Способ лечения при алкогольном делирии
Cui et al. Haruyuki Kamiya, Hokkaido University, Japan Reviewed by: Hiroki Toyoda, Osaka University, Japan
Pickworth Cerebral Ischæmia and Mental Disorder.∗
WO2004064849A1 (fr) Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale
Saadatmand et al. The Effect of Oral Chamomile on Anxiety: A Systematic Review of Clinical Trials
Robinson-Gabel The Potential Viability of Traditional Medicine in The Modern World

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase